|
| 9. |
ACCRUED
EXPENSES AND LONG-TERM LIABILITIES |
Other
accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020:
SCHEDULE
OF OTHER ACCRUED EXPENSES
| |
|
September
30, 2021 |
|
|
December
31, 2020 |
|
| |
|
(unaudited) |
|
|
|
|
| Accrued royalties |
|
$ |
3,572 |
|
|
$ |
2,710 |
|
| Upfront Medicare payment |
|
|
- |
|
|
|
2,066 |
|
| Operating lease liabilities |
|
|
1,030 |
|
|
|
1,027 |
|
| All others |
|
|
1,056 |
|
|
|
1,182 |
|
| Accrued professional fees |
|
|
931 |
|
|
|
854 |
|
| Unclaimed property |
|
|
565 |
|
|
|
565 |
|
| Contingent consideration |
|
|
473 |
|
|
|
398 |
|
| Accrued pharma services invoices |
|
|
438 |
|
|
|
108 |
|
| Taxes payable |
|
|
248 |
|
|
|
334 |
|
| Accrued lab costs - diagnostics |
|
|
514 |
|
|
|
161 |
|
| Financing lease liabilities |
|
|
98 |
|
|
|
177 |
|
| ESPP payable |
|
|
37 |
|
|
|
108 |
|
| Accrued sales and marketing -
diagnostics |
|
|
41 |
|
|
|
51 |
|
| Deferred
revenue |
|
|
40 |
|
|
|
54 |
|
| Total
other accrued expenses |
|
$ |
9,043 |
|
|
$ |
9,795 |
|
Long-term
liabilities consisted of the following as of September 30, 2021 and December 31, 2020:
SCHEDULE OF LONG TERM LIABILITIES
| |
|
September
30, 2021 |
|
|
December
31, 2020 |
|
| |
|
(unaudited) |
|
|
|
|
| Uncertain tax positions |
|
$ |
4,517 |
|
|
$ |
4,342 |
|
| Warrant liability |
|
|
158 |
|
|
|
21 |
|
| Financing lease liabilities |
|
|
75 |
|
|
|
138 |
|
| Deferred
revenue |
|
|
18 |
|
|
|
136 |
|
| Total
other long-term liabilities |
|
$ |
4,768 |
|
|
$ |
4,637 |
|
|